PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping

Abstract

Health-related quality of life (HRQoL) data are routinely used to generate utilities for health technology assessment, with a range of methods available to calculate health state utility values (HSUVs). Values may depend on the questionnaire, value set, and statistical analysis performed. The Phase II VISION study (NCT02864992) of tepotinib in patients with NSCLC harboring METex14 skipping captured both EQ-5D-5L and EORTC QLQ-C30 responses. This study compares alternative HSUVs generated from VISION.